Braveheart, Attovia, Vogenx keep IPOs ballooning with plans to compete in cardiometabolic, immuno

Summary

Three biotech companies—Braveheart Bio, Attovia Therapeutics, and Vogenx—are pursuing IPOs with plans to compete in cardiometabolic and immunology markets against established competitors including Bristol Myers Squibb, Sanofi, and Regeneron.